TY - JOUR
T1 - The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single cell resolution
AU - de Rooij, Laura P M H
AU - Becker, Lisa M
AU - Teuwen, Laure Anne
AU - Boeckx, Bram
AU - Jansen, Sander
AU - Feys, Simon
AU - Verleden, Stijn
AU - Liesenborghs, Laurens
AU - Stalder, Anna K
AU - Libbrecht, Sasha
AU - Van Buyten, Tina
AU - Philips, Gino
AU - Subramanian, Abhishek
AU - Dumas, Sébastien J
AU - Meta, Elda
AU - Borri, Mila
AU - Sokol, Liliana
AU - Dendooven, Amélie
AU - Truong, Anh Co K
AU - Gunst, Jan
AU - Van Mol, Pierre
AU - Haslbauer, Jasmin D
AU - Rohlenova, Katerina
AU - Menter, Thomas
AU - Boudewijns, Robbert
AU - Geldhof, Vincent
AU - Vinckier, Stefan
AU - Amersfoort, Jacob
AU - Wuyts, Wim
AU - Van Raemdonck, Dirk
AU - Jacobs, Werner
AU - Ceulemans, Laurens J
AU - Weynand, Birgit
AU - Thienpont, Bernard
AU - Lammens, Martin
AU - Kuehnel, Mark
AU - Eelen, Guy
AU - Dewerchin, Mieke
AU - Schoonjans, Luc
AU - Jonigk, Danny
AU - van Dorpe, Jo
AU - Tzankov, Alexandar
AU - Wauters, Els
AU - Mazzone, Massimiliano
AU - Neyts, Johan
AU - Wauters, Joost
AU - Lambrechts, Diether
AU - Carmeliet, Peter
N1 - FTX; (CC BY-NC 4.0)
PY - 2022
Y1 - 2022
N2 - Aims: SARS-CoV-2 infection causes COVID-19, which in severe cases evokes life-threatening acute respiratory distress syndrome (ARDS). Transcriptome signatures and the functional relevance of non-vascular cell types (e.g. immune and epithelial cells) in COVID-19 are becoming increasingly evident. However, despite its known contribution to vascular inflammation, recruitment/invasion of immune cells, vascular leakage and perturbed hemostasis in the lungs of severe COVID-19 patients, an in-depth interrogation of the endothelial cell (EC) compartment in lethal COVID-19 is lacking. Moreover, progressive fibrotic lung disease represents one of the complications of COVID-19 pneumonia and ARDS. Analogous features between idiopathic pulmonary fibrosis (IPF) and COVID-19 suggest partial similarities in their pathophysiology, yet, a head-to-head comparison of pulmonary cell transcriptomes between both conditions has not been implemented to date.Methods and results: We performed single nucleus RNA-seq (snRNA-seq) on frozen lungs from 7 deceased COVID-19 patients, 6 IPF explant lungs and 12 controls. The vascular fraction, comprising 38,794 nuclei, could be subclustered into 14 distinct EC subtypes. Non-vascular cell types, comprising 137,746 nuclei, were subclustered and used for EC-interactome analyses. Pulmonary ECs of deceased COVID-19 patients showed an enrichment of genes involved in cellular stress, as well as signatures suggestive of dampened immunomodulation and impaired vessel wall integrity. In addition, increased abundance of a population of systemic capillary and venous ECs was identified in COVID-19 and IPF. COVID-19 systemic ECs closely resembled their IPF counterparts, and a set of 30 genes was found congruently enriched in systemic ECs across studies. Receptor-ligand interaction analysis of ECs with non-vascular cell types in the pulmonary micro-environment revealed numerous previously unknown interactions specifically enriched/depleted in COVID-19 and/or IPF.Conclusions: This study uncovered novel insights into the abundance, expression patterns and interactomes of EC subtypes in COVID-19 and IPF, relevant for future investigations into the progression and treatment of both lethal conditions.Translational perspective: While assessing clinical and molecular characteristics of severe and lethal COVID-19 cases, the vasculature's undeniable role in disease progression has been widely acknowledged. COVID-19 lung pathology moreover shares certain clinical features with late-stage IPF - yet an in-depth interrogation and direct comparison of the endothelium at single-cell level in both conditions is still lacking. By comparing the transcriptomes of ECs from lungs of deceased COVID-19 patients to those from IPF explant and control lungs, we gathered key insights the heterogeneous composition and potential roles of ECs in both lethal diseases, which may serve as a foundation for development of novel therapeutics.
AB - Aims: SARS-CoV-2 infection causes COVID-19, which in severe cases evokes life-threatening acute respiratory distress syndrome (ARDS). Transcriptome signatures and the functional relevance of non-vascular cell types (e.g. immune and epithelial cells) in COVID-19 are becoming increasingly evident. However, despite its known contribution to vascular inflammation, recruitment/invasion of immune cells, vascular leakage and perturbed hemostasis in the lungs of severe COVID-19 patients, an in-depth interrogation of the endothelial cell (EC) compartment in lethal COVID-19 is lacking. Moreover, progressive fibrotic lung disease represents one of the complications of COVID-19 pneumonia and ARDS. Analogous features between idiopathic pulmonary fibrosis (IPF) and COVID-19 suggest partial similarities in their pathophysiology, yet, a head-to-head comparison of pulmonary cell transcriptomes between both conditions has not been implemented to date.Methods and results: We performed single nucleus RNA-seq (snRNA-seq) on frozen lungs from 7 deceased COVID-19 patients, 6 IPF explant lungs and 12 controls. The vascular fraction, comprising 38,794 nuclei, could be subclustered into 14 distinct EC subtypes. Non-vascular cell types, comprising 137,746 nuclei, were subclustered and used for EC-interactome analyses. Pulmonary ECs of deceased COVID-19 patients showed an enrichment of genes involved in cellular stress, as well as signatures suggestive of dampened immunomodulation and impaired vessel wall integrity. In addition, increased abundance of a population of systemic capillary and venous ECs was identified in COVID-19 and IPF. COVID-19 systemic ECs closely resembled their IPF counterparts, and a set of 30 genes was found congruently enriched in systemic ECs across studies. Receptor-ligand interaction analysis of ECs with non-vascular cell types in the pulmonary micro-environment revealed numerous previously unknown interactions specifically enriched/depleted in COVID-19 and/or IPF.Conclusions: This study uncovered novel insights into the abundance, expression patterns and interactomes of EC subtypes in COVID-19 and IPF, relevant for future investigations into the progression and treatment of both lethal conditions.Translational perspective: While assessing clinical and molecular characteristics of severe and lethal COVID-19 cases, the vasculature's undeniable role in disease progression has been widely acknowledged. COVID-19 lung pathology moreover shares certain clinical features with late-stage IPF - yet an in-depth interrogation and direct comparison of the endothelium at single-cell level in both conditions is still lacking. By comparing the transcriptomes of ECs from lungs of deceased COVID-19 patients to those from IPF explant and control lungs, we gathered key insights the heterogeneous composition and potential roles of ECs in both lethal diseases, which may serve as a foundation for development of novel therapeutics.
U2 - 10.1093/cvr/cvac139
DO - 10.1093/cvr/cvac139
M3 - A1: Web of Science-article
C2 - 35998078
SN - 0008-6363
VL - 119
SP - 520
EP - 535
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 2
ER -